Payment overview · 2025
General Payments
$5,951.87
29 reported records · 8 companies
Healthcare provider profile · identity verified
Curtis J. Mello, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH DARTMOUTH, MA · NPI 1124080312
Verified facts
What the public records show
CMS Open Payments records show Curtis J. Mello, MD received $5,951.87 in general payments during 2025 across 29 reported records.
Viatris Specialty LLC accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $3,036.55 | 51.0% | 5 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $2,377.21 | 39.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $221.08 | 3.7% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $183.10 | 3.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.73 | 0.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.09 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.47 | 0.4% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $20.64 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,017.62 | 2 |
| Travel and Lodging | $2,288.36 | 1 |
| Food and Beverage | $611.89 | 25 |
| Education | $34.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $3,036.55 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $176.15 | 8 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $143.12 | 5 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $97.69 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.28 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.09 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $6.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 326 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
206 | 64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
326 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 661 | 169 |
| Prednisone | Prednisone | 650 | 190 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 548 | 195 |
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 35 |
| Trazodone Hcl | Trazodone Hcl | 382 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 326 | 51 |
| Gabapentin | Gabapentin | 274 | 28 |
| Simvastatin | Simvastatin | 258 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 238 | 40 |
| Mirtazapine | Mirtazapine | 225 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 217 | 53 |
| Symbicort | Budesonide/Formoterol Fumarate | 206 | 64 |
| Furosemide | Furosemide | 178 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 177 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 16 |
| Azithromycin | Azithromycin | 172 | 89 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 163 | 34 |
| Omeprazole | Omeprazole | 162 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 162 | 52 |
| Donepezil Hcl | Donepezil Hcl | 151 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 150 | 52 |
| Lisinopril | Lisinopril | 145 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | suppressed |
| Potassium Chloride | Potassium Chloride | 132 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 120 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 13 |
| Arnuity Ellipta | Fluticasone Furoate | 116 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 111 | 22 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 101 | 20 |
| Sertraline Hcl | Sertraline Hcl | 97 | 11 |
| Alprazolam | Alprazolam | 88 | 18 |
| Memantine Hcl | Memantine Hcl | 84 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 82 | suppressed |
| Metformin Hcl | Metformin Hcl | 80 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 72 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 67 | suppressed |
| Dulera | Mometasone/Formoterol | 66 | 20 |
| Colchicine | Colchicine | 63 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 29 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Allopurinol | Allopurinol | 58 | suppressed |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Eliquis | Apixaban | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 51 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Timolol Maleate | Timolol Maleate | 40 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 24 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 12 |
| Ofev | Nintedanib Esylate | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 26 |
| Meloxicam | Meloxicam | 31 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 28 | suppressed |
| Dupixent Syringe | Dupilumab | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Roflumilast | Roflumilast | 27 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Perphenazine | Perphenazine | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Minoxidil | Minoxidil | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | suppressed |
| Losartan Potassium | Losartan Potassium | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Dupixent Pen | Dupilumab | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Pulmicort Flexhaler | Budesonide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,951.87 · 29 records | Viatris Specialty LLC | AIRSUPRA, FASENRA, JASCAYD, LUNA, NUCALA, Ohtuvayre, TEZSPIRE, TRELEGY ELLIPTA, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error